Key facts
- EU health ministers have directed the European Commission to investigate the effects of US drug pricing policies.
- The probe will examine if US 'most favored nation' (MFN) pricing is causing delayed drug launches and increased prices in the EU.
- President Trump's executive order in May aimed to align drug prices with the lowest rates in developed nations.
- A Reuters analysis indicated a 35% drop in drug launches in EU markets following the US policy shift.
- The European Commission will determine the impact on specific pharmaceuticals, new product introductions, and potential market exits by drugmakers.
The European Commission has been tasked by EU health ministers to investigate the repercussions of US President Donald Trump's drug pricing policies on the European bloc. Concerns have been raised that the US 'most favored nation' (MFN) pricing strategy, which aims to align drug prices with the lowest rates among developed nations, could be leading to delayed drug launches and significantly higher prices in the EU.
President Trump issued an executive order in May that compels pharmaceutical companies to adopt this MFN pricing approach. Given that the US represents the world's largest pharmaceutical market, drugmakers may prioritize higher prices or delay launches in smaller markets like Europe to maximize revenue and profit margins.
Evidence suggests this may already be occurring. A Reuters report in March, citing an analysis by market research firm GlobalData, indicated a roughly 35% decrease in drug launches within EU markets during the 10 months following the implementation of Trump's executive order, compared to the preceding 10-month period.
Health ministers are seeking clarity on whether the MFN policy is indeed causing these delays and price increases, ultimately impacting patient access to innovative medicines. The European Commission will examine which specific pharmaceuticals are affected, the consequences for new product introductions, and the possibility of some drugmakers withdrawing from the European market altogether.
Health Commissioner Olivér Várhelyi stated that the EU executive aims to conduct this assessment swiftly, ideally before the summer break, to address the urgency of the matter.